{"id":4656,"date":"2018-10-02T00:02:00","date_gmt":"2018-10-01T22:02:00","guid":{"rendered":"https:\/\/patientenstimme-sma.de\/?page_id=4656"},"modified":"2026-03-16T21:04:51","modified_gmt":"2026-03-16T20:04:51","slug":"phase-3-studie-zu-avxs-101","status":"publish","type":"post","link":"https:\/\/smartunity.space\/stories\/thema\/phase-3-studie-zu-avxs-101\/","title":{"rendered":"Phase 3 Studie zu AVXS-101"},"content":{"rendered":"\n<p class=\"tw-text-wide\">AveXis startet Phase 3 Studie &#8220;<a href=\"http:\/\/www.smasupportuk.org.uk\/blog\/treatments-research\/avexis-clinical-trial-for-infants-aged-less-than-six-months-old-with-sma-type-1-in-the-uk\" target=\"_blank\" rel=\"noopener noreferrer\">STR1VE-EU<\/a>&#8221; mit Type 1 Kindern im Alter bis zu max. 6 Monaten. Begonnen wird in Italien und UK. EU-weit sollen etwa 30 Patienten in 16 Kliniken in Italien, UK, Frankreich, Spanien, Niederlande, Schweden, Belgien und auch Deutschland teilnehmen k\u00f6nnen. Die Patienten d\u00fcrfen nur ein oder zwei SMN2-Kopien haben.<\/p>\n\n\n\n<p class=\"tw-text-wide\">Quelle: <a href=\"http:\/\/www.smasupportuk.org.uk\/blog\/treatments-research\/avexis-clinical-trial-for-infants-aged-less-than-six-months-old-with-sma-type-1-in-the-uk\" target=\"_blank\" rel=\"noopener noreferrer\">http:\/\/www.smasupportuk.org.uk\/blog\/treatments-research\/avexis-clinical-trial-for-infants-aged-less-than-six-months-old-with-sma-type-1-in-the-uk<\/a> (link defekt)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AveXis startet Phase 3 Studie &#8220;STR1VE-EU&#8221; mit Type 1 Kindern im Alter bis zu max. 6 Monaten. Begonnen wird in Italien und UK. EU-weit sollen etwa 30 Patienten in 16 Kliniken in Italien, UK, Frankreich, Spanien, Niederlande, Schweden, Belgien und auch Deutschland teilnehmen k\u00f6nnen. Die Patienten d\u00fcrfen nur ein oder zwei SMN2-Kopien haben. Quelle: http:\/\/www.smasupportuk.org.uk\/blog\/treatments-research\/avexis-clinical-trial-for-infants-aged-less-than-six-months-old-with-sma-type-1-in-the-uk [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"only-view","format":"standard","meta":{"activitypub_content_warning":"","activitypub_content_visibility":"local","activitypub_max_image_attachments":0,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"","footnotes":""},"categories":[1],"tags":[58],"class_list":["post-4656","post","type-post","status-publish","format-standard","hentry","category-thema","tag-smanews"],"_links":{"self":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/comments?post=4656"}],"version-history":[{"count":2,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4656\/revisions"}],"predecessor-version":[{"id":39924,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4656\/revisions\/39924"}],"wp:attachment":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/media?parent=4656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/categories?post=4656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/tags?post=4656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}